Acetazolamide
A medication that reduces the production of fluid in the eye and brain by inhibiting an enzyme called carbonic anhydrase, making it useful for glaucoma, altitude sickness prevention, and certain types of epilepsy. It also promotes the excretion of bicarbonate in the urine, which can help correct certain acid-base disturbances in the body. Patients may notice increased urination and a tingling sensation in the hands and feet, which are common and expected effects.
분자량
222.3000 g/mol
LogP
-0.30
TPSA
152.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D 구조
Cite this structure
Embed this structure
SMILES
CC(=O)Nc1nnc(S(N)(=O)=O)s1
InChI
InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
Molecular Formula
C4H6N4O3S2
HBD / HBA
2 / 7
회전 가능 결합
2
무거운 원자
13
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
A medication that reduces the production of fluid in the eye and brain by inhibiting an enzyme called carbonic anhydrase, making it useful for glaucoma, altitude sickness prevention, and certain types of epilepsy. It also promotes the excretion of bicarbonate in the urine, which can help correct certain acid-base disturbances in the body. Patients may notice increased urination and a tingling sensation in the hands and feet, which are common and expected effects.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Acetazolamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL20. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 1986. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acetazolamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acetazolamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acetazolamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acetazolamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acetazolamide"></drugfyi-drug>